Description
Product Specifications
- Product: Eloralintide 10mg
- Compound / formulation: Eloralintide (LY3841136)
- Labeled quantity / volume: 10mg per vial
- Physical form: White lyophilized powder
- Research focus: Amylin receptor signaling and appetite regulation
- Available batch identifiers: Red cap — Chromate report #41906
- SKU: HOP-ELORALINTIDE-10MG
- Intended classification: Laboratory research only
Independent Laboratory Testing
- Red cap — Chromate report #41906: View Certificate of Analysis
- Identity: Eloralintide
- Measured quantity: 12.55mg per vial
- Purity: 99.084%
- Sterility: Pass
- Endotoxins: 0.9537 EU/vial
- Analysis conducted: November 5, 2026
House of Peptides maintains an established testing and sampling protocol with its suppliers. Under this agreed protocol, samples are randomly selected from a production batch and submitted for independent laboratory analysis.
The submitted samples are drawn from the same production batch as the corresponding inventory supplied to House of Peptides. This batch-based sampling approach provides analytical information associated with the production batch rather than individual testing of every vial.
House of Peptides may maintain inventory from multiple production batches of the same compound. Each Certificate of Analysis corresponds to its identified batch, which may be distinguished by cap color or lot designation. Orders are fulfilled on a first-in, first-out (FIFO) basis, so the batch supplied depends on available inventory at the time of fulfillment. Laboratory findings apply to the submitted samples from their respective batches, not to every individual vial.
Scientific Research Background
Amylin is a hormone released by the pancreas after eating. It helps the body regulate appetite and the feeling of fullness.
Eloralintide, also known by its development code LY3841136, is a synthetic peptide designed to activate amylin receptors. A compound that activates a receptor is called an agonist.
Researchers are particularly interested in its preference for the amylin 1 receptor, or AMY1R. Laboratory experiments found stronger activity at this receptor than at certain related receptors.
This selectivity gives scientists a way to investigate how different receptor patterns influence a compound’s effects. It does not, by itself, establish better results or fewer adverse effects in people.
Eloralintide has been investigated in laboratory experiments, animal studies, and human clinical trials. Eli Lilly and Company is developing it as an investigational medicine, both alone and in combination with other therapies.
Clinical Research Observations
1. Why are scientists interested in eloralintide and fullness?
Feeling full helps us decide when to stop eating. A hormone called amylin is part of this process.
Eloralintide is designed to activate some of the same receptors—the places on cells that receive amylin’s signals.
What researchers found: In laboratory tests using human receptors, one type of amylin receptor responded to lower amounts of eloralintide than the related receptors tested.
Why it matters: This helps scientists explore how fullness signals may influence appetite and body weight. Laboratory tests alone cannot tell us how much weight a person might lose.
2. What did an early human study show?
Early studies help researchers learn what happens when a compound is studied in people.
A 12-week study compared eloralintide with a placebo—a treatment without the study compound—in 100 people with obesity or overweight.
What researchers found: People in several eloralintide groups lost more weight, on average, than those given placebo. Researchers also measured how the compound entered and stayed in the bloodstream.
Why it matters: The results gave researchers a reason to conduct larger studies. Twelve weeks is too short to answer questions about lasting benefits or long-term safety.
3. What did a longer study find about weight loss?
A larger study followed 263 adults for 48 weeks. They had obesity, or were overweight with another weight-related health problem. None had type 2 diabetes.
What researchers found: The 2025 study reported estimated average weight loss of about 9% to 20% across eloralintide groups, compared with 0.4% for placebo. These figures came from an analysis that assumed people continued their assigned treatment.
Why it matters: A longer study gives researchers a better picture of weight changes over time. These percentages describe averages across groups; they do not tell us how much any one person would lose.
4. What side effects did researchers observe?
Researchers look at more than the number on the scale. They also track how people feel and why some leave a study or stop treatment.
What researchers found: Feeling sick to the stomach and feeling tired were among the most common problems reported in the larger study. In the earlier 12-week study, researchers also recorded slower pulse rates. Four people had mood changes, and three people in one group stopped treatment after mood changes.
Why it matters: Weight loss is only one part of the picture. Researchers also need to understand unwanted effects and whether people can continue treatment comfortably and safely.
5. Has eloralintide been studied with tirzepatide?
Eloralintide and tirzepatide work through different hormone signals. Scientists have studied whether using them together changes the results.
What researchers found: In September 2026, Lilly reported a 48-week study of 367 adults with obesity or overweight and type 2 diabetes. Average weight loss was estimated at 23.3% in the group receiving the highest tested combination, compared with 14.8% for tirzepatide alone. Stomach and digestive problems were more common in the combination groups.
Why it matters: These results were reported by Lilly and concern two compounds studied together. They do not show that eloralintide alone produces the same weight loss.
6. Has eloralintide received FDA approval?
No. As of October 29, 2026, eloralintide is still being studied and has not received FDA approval.
What researchers found: Lilly’s September 2026 update describes ongoing phase 3 trials. These are later-stage studies intended to learn more about how well eloralintide works and its safety.
Why it matters: Reaching a later stage of research does not mean a compound has been approved. House of Peptides’ research vial is not an FDA-approved medicine or a substitute for prescription treatment.
7. What is the overall scientific takeaway?
Eloralintide has attracted interest because it acts on signals involved in feeling full.
What researchers found: Studies in people have reported weight loss, along with unwanted effects that need continued attention. Results also differ depending on whether eloralintide was studied alone or with another compound.
Why it matters: The research is encouraging, but important questions remain about lasting benefits and safety. Findings from clinical studies cannot automatically be applied to this particular research product.
Published Scientific Research
- Briere et al. (2025) — Discovery and receptor activity. Molecular Metabolism, 102:102271. Laboratory receptor experiments, animal studies, and an initial human trial. The receptor observations above concern laboratory assays using human receptors. Read paper. DOI:
10.1016/j.molmet.2025.102271. Supports: Background; Question 1. - Bhattachar et al. (2026) — Phase 1 proof of concept. Diabetes, Obesity and Metabolism, 28(4):2651–2660. A 12-week, randomized, placebo-controlled study of 100 participants with obesity or overweight. Read paper. DOI:
10.1111/dom.70439. Supports: Questions 2 and 4. - Billings et al. (2025) — Phase 2 weight-management trial. The Lancet, 406(10520):2631–2643. A 48-week, randomized, placebo-controlled trial of 263 participants without type 2 diabetes. PubMed — PMID 41207310. DOI:
10.1016/S0140-6736(25)02155-5. ClinicalTrials.gov — NCT06230523. Supports: Questions 3 and 4. - Eli Lilly and Company (September 30, 2026) — Eloralintide and tirzepatide combination results. Sponsor announcement reporting a 48-week phase 2b trial in 367 adults with obesity or overweight and type 2 diabetes. This source is a company report, rather than a peer-reviewed full trial publication. Read announcement. Supports: Question 5.
- Eli Lilly and Company (updated September 2026) — Current development overview. Describes eloralintide’s investigational status, amylin signaling, and ongoing phase 3 development. Read development overview. Supports: Background; Question 6.
Understanding the Research Findings
The clinical findings above relate to investigational materials evaluated in Eli Lilly’s studies. Identifying the compound does not establish identical formulation, pharmaceutical quality, safety, or clinical outcomes. Eloralintide remains investigational; House of Peptides’ research product is not FDA-approved or represented as equivalent to clinical-trial materials.
House of Peptides is not affiliated with or endorsed by Eli Lilly and Company.
Research Use Notice
For laboratory research only. Not intended for human or veterinary administration, diagnostic, or therapeutic use.
Reviews
There are no reviews yet.